20/20 Biolabs, Inc. Common Stock(AIDX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.2
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for AIDX

11/13/2026: AIDX (1-star) is currently NOT-A-BUY. Pass it for now.

20/20 Biolabs is a micro-cap healthcare diagnostics company that develops AI-powered multi-cancer early detection blood tests and laboratory incubation services. The company's primary strength lies in its innovative OneTest screening platform and CLIAx laboratory accelerator model. Its main growth opportunity centers on increasing adoption of preventative oncology screening, though it faces heavy risks from intense industry competition, tight financial liquidity, and persistent net losses. The stock is best suited for speculative or momentum-oriented investors who can tolerate high volatility, while key developments to monitor include commercial test adoption rates and capital-raising milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitWhile operating in a high-growth sector, the company's micro-cap scale and revenue consistency present high execution risks.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp speculative price movements and high volatility that attract short-term momentum traders.
Value investorMixed fitLow valuation multiples reflect deeply depressed share prices, but ongoing net losses obscure true fundamental value.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for survival and growth.
Low-risk investorWeak fitExtreme price volatility and micro-cap liquidity risks make it unsuitable for conservative portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock experiences wide daily price swings and extreme historical drawdowns.
Valuation riskMedium / highDepressed market capitalization reflects ongoing distress and operational uncertainty.
Competition risk (large diagnostics and genomic testing competition)HighWell-capitalized industry giants dominate market share and lab testing channels.
Business qualityMediumInnovative AI screening concepts are challenged by limited commercial scale.
Dividend incomeLow / noneNo cash returns are distributed to equity holders.
Execution riskHighManagement must successfully scale commercial distribution channels with tight liquidity.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.73M USD
Price to earnings Ratio -
1Y Target Price 5
Price to earnings Ratio -
1Y Target Price 5
Volume (30-day avg) 211.6K shares
Beta -0.42
52 Weeks Range 0.18 - 50.00
Updated Date 11/15/2026
52 Weeks Range 0.18 - 50.00
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.75

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -23.81%
Avg. Invested days 8
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
AIDX receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
AIDX has moderate overall fundamentals (3 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+32.7%) and solid revenue growth (+16.7%) are partially offset by weak cash generation (FCF margin -93.9%), weak profitability (net margin -182.8%).

Financial Health Rating

★★★★★
AIDX's financial health is soft, with the relatively strongest area being soft liquidity, including working-capital and asset support (WC/assets -24.0%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is AIDX's strongest growth driver at +32.7% FY2025 versus FY2024 (solid, 4 stars). Revenue growth (+16.7%, solid) and free-cash-flow growth (+26.1%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 3.6% and approximately 81.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 15.56% supports management-shareholder alignment.

Top 5 Institutional Investors

Cresset Asset Management, LLC 1.96%
HRT FINANCIAL LLC 0.73%
Vanguard Fiduciary Trust Co 0.43%
Geode Capital Management, LLC 0.40%
Atlantic Union Bankshares Corp 0.29%

Unit Economics (Per $1K Revenue)

★★★★★
AIDX generates approximately $296 of gross profit, $-1,629 of operating income, and $-939 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
AIDX has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Oncology & Wellness TestingCommercial laboratory fees generated from tests like OneTest for Cancer and OneTest for Longevity.The company sells specialized cancer and health screening blood tests directly to consumers and through clinical channels.
Laboratory Services & AcceleratorsRevenue from operating the CLIAx facility, providing testing infrastructure and regulatory support for diagnostic partners.It rents out specialized laboratory capacity and offers validation services to international medical startups entering the US market.

Valuation

Trailing PE -
Forward PE -
Enterprise Value -1.24M
Price to Sales(TTM) 1.34
Enterprise Value -1.24M
Price to Sales(TTM) 1.34
Enterprise Value to Revenue 0.01
Enterprise Value to EBITDA -
Shares Outstanding 13.37M
Shares Floating 10.84M
Shares Outstanding 13.37M
Shares Floating 10.84M
Percent Insiders 15.56
Percent Institutions 3.57

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.